Early-onset dystonia is an autosomal dominant movement disorder associated with deletion of a glutamic acid residue in torsinA. We generated four independent lines of transgenic mice by overexpressing human ∆E-torsinA using a neuron specific enolase promoter. The transgenic mice developed abnormal involuntary movements with dystonic-appearing, selfclasping of limbs, as early as 3 weeks after birth. Animals also showed hyperkinesia, and rapid bi-directional circling. Approximately 40% of transgenic mice from each line demonstrated these severe behavioral abnormalities. Neurochemical analyses revealed decreases in striatal dopamine in affected transgenic mice while levels were increased in those that had no behavioral changes.
Introduction
Early-onset DYT1 dystonia is a potentially disabling form of primary dystonia that is characterized by sustained or repetitive involuntary muscle contractions and abnormal postures (1-3). The disease typically manifests between the ages of 5 and 26 years (3), and is inherited in an autosomal dominant manner with a penetrance of about 30-40% (4) (5) (6) . The reasons for the decreased penetrance in humans are not known. Most cases of early-onset dystonia are caused by a 3-base pair (GAG) deletion in the DYT1 gene on chromosome 9q34, resulting in loss of a glutamic acid residue (∆E) in the protein torsinA (7) . An 18-bp deletion in the DYT1 gene leading to loss of 6 amino acids (residues 323-328) in torsinA has also been described in a single patient with early onset dystonia with myoclonic features (8) .
TorsinA mRNA and protein are widely expressed in peripheral tissues (7, 9) , but are restricted to neurons in the central nervous system (9) (10) (11) (12) . In developing rats, torsinA expression is maximal at E20 or E21 (postnatal day 1) in the brain and in peripheral tissues, except in the cerebellum where peak expression is observed at E14 (13) . The function of torsinA is not known, but it has homology to HSP/Clp proteins (14, 15) , a subclass of AAA + (ATPases associated with cellular activities) proteins, suggesting that it may have chaperone-like function. Indeed, a neuroprotective function for torsinA has recently been demonstrated in both in vitro and in vivo models (16) (17) (18) (19) consistent with a chaperone function for this protein.
The pathophysiology of early onset dystonia is poorly understood and there is no specific therapy for this potentially disabling condition. A Drosophila model of early onset dystonia has recently been reported, (20) . We now report, for the first time, that overexpression of ∆E-torsinA in generates a transgenic mouse model of early onset dystonia with a behavioral phenotype and pathologic and neurochemical changes similar to those found in patients with the disease.
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RESULTS

Generation of transgenic mice expressing human ∆E-torsinA
We generated multiple (four) transgenic mice overexpressing human ∆E-torsinA using a rat neuron-specific enolase promoter and compared the phenotype with wild type control mouse.
The schema of the DNA construct used for the production of transgenic mice is shown in Fig. 1a .
Genotype analysis performed on DNA isolated from tail biopsies from each of the transgenic mouse lines showed incorporation of ∆E-torsinA cDNA, as demonstrated by the absence of one of the BseRI restriction sites (Fig. 1b) . All four independent transgenic lines were confirmed by southern blot analysis. Expression of the transgene was further analyzed by RT-PCR on brain samples obtained from wild type and transgenic animals. Mutant torsinA mRNA was expressed in each of the transgenic lines but not in the wild type animals (Fig. 1c) . Western blot analysis demonstrated varying levels of torsinA protein expression in the different transgenic lines, but in each case levels were higher than in the wild type controls (Fig 1d) .
Transgenic mice demonstrate abnormal behaviors
Approximately 40% of transgenic mice from each line expressing ∆E-torsinA displayed an abnormal behavior on visual inspection (102 out of a total of 252 transgenic animals). In the large majority of the "affected" animals, behavioral changes were apparent by 3 weeks after birth, although behavioral changes emerged at 10 weeks in one animal. The severity of symptoms increased with age in all animals. The transgenic animals showed normal weight gain and reproduced normally, but affected mothers had difficulty nursing due to their hyperkinetic behavior.
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When affected transgenic mice were hung by their tails, they exhibited dystonicappearing movements of limbs with self-clasping (Fig. 2 ). This self-clasping behavior was observed in transgenic mice derived from all four independent lines (42 animals out of 66 from Tg#13, 5 out of 14 from TG#22, 5 out of 14 from TG#35 and 6 out of 12 animals from TG#49).
Four animals (from line Tg#13) also demonstrated intermittent periods of abnormal shaking of the head from side to side and sustained deviation of the head toward one side or the other (Fig   2) .
In the computerized activity monitoring system, affected transgenic animals had significantly greater horizontal activity and traveled greater distances than did wild type animals, although the degree of hyperactivity varied between the different transgenic lines (Fig. 3a ) but differences were not significant between transgenic except for TG#13. Transgenic mice that did not show a behavioral phenotype on visual inspection, nonetheless had significant hyperactivity in comparison to wild type controls, although hyperactivity was less than what was observed in animals demonstrating an overt behavioral abnormality (Fig. 3b ).
Transgenic animals also demonstrated abnormal circling behavior, with alternations varying between clockwise and counter clockwise rotations in the same animal (Fig. 3c ).
Circling behavior was noted only in animals that expressed dystonic like movements of the limbs and varied in frequency between the different lines, with some animals turning as frequently as 1-2 times per second. In order to test whether the circling behavior was due to a vestibular or cochlear malfunction, startle chamber/auditory evoked brain stem responses (ABR) were performed to assess cochlear function (3 affected and 3 controls) and a swim test was used to assess vestibular function (6 affected and 6 controls). Cochlear and vestibular functions were 6 normal in all animals tested, although affected animals exhibited hyperactivity and circling behaviors on the swim test compared to the wild type controls (data not shown).
No abnormal behaviors were observed in any of the wild type control mice (n=100).
Neuropathology
Brain sections were immunostained with antibodies to torsinA, ubiquitin, MAP2, PDI and lamin to determine if these proteins accumulate, aggregate and/or form inclusion bodies in transgenic mice as we have described in DYT1 patients (21) . In control animals, cellular immunoreactivity for torsinA and ubiquitin was low and diffuse throughout the cytoplasm of cells in most brain regions. However in transgenic mice, there were perinuclear aggregates and/or inclusions that stained positively for ubiquitin and torsinA. These were most prominent in cholinergic neurons of the pontine and mesencephalic brain stem consistent with the region of the pedunculopontine nucleus (PPN). They were also noted in pontine neurons and in nerve cells of the peri-aqueductal gray region ( Fig.4a and 4b ), but were not detected in other brain areas studied including the cerebral cortex, cerebellum, striatum, hippocampus, and substantia nigra pars compacta (SNc). A generalized increase in ubiquitinated proteins by immunofluorescence was observed in brain sections of transgenic mice.
Neurochemical analyses show an alteration in striatal dopamine levels in transgenic mice.
HPLC analysis of brain homogenates obtained from the striata of wild type control mice and transgenic mice showed alteration in dopamine levels (Fig. 5) . In comparison to wild type control animals, the dopamine levels were decreased (-39%, p=0.031) in transgenic animals that exhibited an abnormal behavioral phenotype, while dopamine levels were increased (+18%, p=0.035) in transgenic animals that had no obvious behavioral phenotype (unaffected). The 7 striatal DOPAC/DA ratio was decreased in both affected (-8%) as well as unaffected (-33%) transgenic animals when compared to the control mice.
DISCUSSION
We describe, for the first time, the generation of a transgenic mouse model of DYT1 dystonia that has an abnormal behavioral phenotype with dystonia-like contractions in all limbs, and hyperkinetic activities. These features were observed in four independent transgenic mouse lines, indicating that this behavioral phenotype is independent of site of integration but a direct result of the ∆E-torsinA protein.
In the present study, we did not express wild type torsinA in transgenic mice for several reasons. Previously, we and others demonstrated that the overexpression of wild type, but not mutant, torsinA protected cultured cells from cellular insults (16, 18, 19) , and decreased polyglutamine aggregates in C. elegans (17) . Similarly, overexpression of mutant torsinA induced behavioral and pathological changes in Drosophila, which were not seen with wild type overexpression (20) . Thus, unlike mutant torsinA, overexpression of wild type torsinA does not have any adverse effects in vitro or in vivo, making it unlikely that expression of wild type torsinA would cause pathological or behavioral changes in transgenic mice. Therefore, all comparisons of the DYT1 transgenic mice in this study were done with wild type control mice.
DYT1 dystonia is a clinical disorder that typically manifests during childhood (3).
Approximately 30-40% of patients who carry the DYT1 gene mutation manifest dystonic symptoms. In transgenic mice, behavioral abnormalities developed at a young age 8 (approximately 21 days postnatal) and the penetrance rate was approximately 40%. Mice that did not appear to be affected on routine observation nonetheless had hyperkinetic activity when tested in the Activity Meter. Interestingly, there is evidence that human DYT1 carriers may also not be completely normal as evidenced by abnormal brain networks and learning (22) .
The reason for the reduced penetrance in transgenic animals is not known as they have similar a genetic background and are bred under identical environmental conditions. However, as the founder transgenic mice were derived from F1 hybrid mice there could be heterogeneity between the founders and their subsequent offspring, even when the founders are mated with an inbred animal. If the incomplete penetrance relates to genetic factors, it is reasonable to suggest that making the mice congenic (by back-crossing with an inbred strain) so as to provide a more homogeneous genetic background, the level of penetrance might increase. An alternative explanation for the incomplete penetrance relates to the putative role of torsinA. The precise function of TorsinA is not known, but it is thought to function as a chaperone protein which promotes the degradation of unwanted proteins (14) . Variability in protein load and/or the activity of degradation enzymes in individual animals could possibly account for the variability in the pathological process and therefore the manifestation of behavioral features.
The molecular mechanisms underlying the neuropathology of DYT1 dystonia are not clearly understood. Most some studies have shown no apparent structural abnormalities (23), but there are isolated reports of an increase in the size of dopamine neurons in the substantia nigra pars compacta (24) and mild neuronal loss with occasional neurofibrillary tangles in the locus ceruleus, substantia nigra pars compacta, pedunculopontine nucleus, and dorsal raphe nucleus 9 (25). More recently, we have used highly sensitive antibodies that detect ubiquitinated-protein conjugates (UPC) to examine brains from human DYT1 patients. These studies demonstrate UPC positive inclusions that also stain positively for torsinA in neurons of the brain stem, notably in the pedunculopontine nucleus (PPN) and periaqueductal gray (PAG) (21) . Consistent with human pathology, we found similar inclusion bodies and protein aggregates that were torsinA and ubiquitin positive, in neurons of the PPN and PAG of ∆E-torsinA transgenic animals, but not controls. These inclusions were localized to the perinuclear region of neurons and stained positively for lamin, a marker of the nuclear envelope. This is similar to what has been observed in cultured cells that overexpress ∆E-torsinA and in humans with the DYT1 mutation (21, (26) (27) (28) . Although, torsinA is present throughout the central nervous system, relatively high levels are detected in the pons in normal rodents (12) . Thus, the appearance of pathological changes in the PPN, PAG and pontine nuclei in these transgenic animals could be a reflection of increased expression of ∆E-torsinA in these areas. These findings raise the possibility that altered neuronal activity in these brainstem regions could contribute to the pathophysiology of DYT1 dystonia.
Studies in a small number of clinically affected patients with DYT1 dystonia have shown reduced striatal dopamine levels (29) . In comparison to wild type control animals, dopamine levels were significantly decreased in transgenic animals with an abnormal behavioral phenotype Additionally, several types of dystonia result from the deficiency of dopamine resulting in alteration in the components of dopamine pathway. Reduced levels of dopamine result in hypofunction of dopamine D2-receptors and may be a common feature of many of these heritable and secondary dystonic syndromes (37) . In addition, medications that enhance dopamine function have been reported to improve the symptoms of dystonia (38, 39) , however benefits are typically modest suggesting a more complex pathophysiology.
The PPN has only recently been implicated in dystonia (21) . The PPN is thought to be involved in the initiation and modulation of movements and other stereotyped behavior (40-42).
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The PPN receives major inputs from the globus pallidus pars interna (GPi), subthalamic nucleus After the microinjections were completed, surviving eggs were reimplanted into the oviducts of pseudopregnant Swiss Webster (SW) female mice. After a gestation period of 19 days, the pups were usually born naturally, although a small fraction were delivered by c-section followed by fostering onto lactating mothers. At 10-14 days, the pups were marked by ear notches and small tail biopsies were performed for the isolation of DNA samples for genotype analysis. After 19-21 days, the pups were weaned. All animal experiments were performed in accordance with the National Institutes of Health guidelines and with the approval of Institutional Animal Care and Use Committee. We did not generate transgenic mice overexpressing wild type torsinA in this study.
Genotype analysis. Polymerase chain reaction (PCR) was performed on genomic DNA isolated from tail biopsies of transgenic and wild type mice. Normal and ∆E-torsinA cDNAs served as positive controls. PCR was performed using the following primer sets: sense primer 5'-CCTGGAATACAAACACCTA-3' and antisense primer 5'-CAGTGACTCCGGCTGCCAATC.
Taq DNA polymerase was used to amplify the DNA with the following conditions: 94°C for 1 min, 55°C for 1 min and 72°C for 1 min, 30 cycles were performed. The PCR products were digested with the restriction enzyme BseRI to further identify the amplified DNA products for GAG deletion. The GAG deletion in ∆E-torsinA cDNA results in the elimination of a restriction site for the enzyme BseRI, which recognizes the DNA sequence GAG/GAG.
Reverse transcription and polymerase chain reaction (RT-PCR).
Total RNA from wild type and DYT1 transgenic mice brains were isolated using RNA isolation kit from Qiagen (Valencia, CA). 5 µg total RNA isolated was reverse transcribed by using one step RT-PCR kit (Qiagen, Valencia, CA). PCR was performed on the reverse transcribed sample using the same set of primers that was used for genotyping as described above.
Western blotting. Western blotting was performed using tissue homogenates obtained from wild type and transgenic mice, using rabbit polyclonal antibody to human torsinA, generated against a peptide derived from the C-terminus as described previously (9) . The antibody has been previously characterized and shown to immunoreact with human and rodent torsinA, and human ∆E-torsinA (9, 12) . Protein concentrations were determined using a protein assay kit (Sigma Diagnostics, St. Louis, MO). Brain homogenates containing 20 µg of protein was resolved on SDS-PAGE and electroblotted onto a PVDF membrane using 50 mM Tris-HCl buffer (pH 8.4). Behavioral studies. Motor function was assessed using a computerized three-dimensional activity monitoring system (AccuScan Instruments, Columbus, OH). The Activity monitor has 32 infrared sensor pairs with 16 along each side spaced 2.5 cm apart and 2.3 cm from the floor.
This system determines motor activity based on the frequency of interruptions to infrared beams traversing the x, y, and z planes. Total distance (cm) traveled and rearing activity and circling were automatically determined from the interruptions of beams in the horizontal and vertical planes, respectively. Mice exhibiting hyperkinetic movements were selected for comparison among different transgenic lines and wild type controls for horizontal and circling activities.
Behavioral data were collected for 30 minutes and expressed as 5-minute blocks. The animals were also videotaped from time to time to record various types of abnormal movements.
Auditory evoked brain stem response (ABR):
Mice were anaesthetized with ketamine (25 mg/kg) and auditory stimuli were independently delivered at a rate of 9.7Hz to the right and left external ear canals via hollow tubes that were wrapped in sound proofing material. The auditory stimulus was a broadband click (0.1ms duration) generated by a Grass auditory stimulator by guest on 
